Globus Medical Acquires Nevro Corp to Enhance Chronic Pain Management Solutions
- Globus Medical plans to acquire Nevro Corp. for $250 million to enhance chronic pain management solutions.
- The acquisition aims to integrate Nevro’s advanced HFX iQ™ spinal cord stimulation system for effective pain relief.
- This strategic move positions Globus Medical as a stronger player in chronic pain treatment and market expansion.
Strategic Acquisition to Enhance Pain Management Solutions
Globus Medical is poised to strengthen its position in the chronic pain management market through its strategic acquisition of Nevro Corp. for approximately $250 million. This agreement, which awaits shareholder and regulatory approvals, marks a significant development in the medical device industry, particularly for companies focused on innovative treatment solutions for chronic pain. By acquiring Nevro, Globus aims to integrate Nevro’s advanced technologies, including the HFX iQ™ spinal cord stimulation system, which has recently demonstrated effective pain relief in clinical studies. The acquisition is expected to close in the second quarter of 2025, positioning Globus to leverage Nevro’s established market presence and innovative therapies.
Despite Nevro reporting a 9.1% decline in fourth-quarter revenue compared to the previous year, the strategic decision to acquire the company reflects a long-term vision for growth and innovation. CEO Kevin Thornal emphasizes the importance of operational improvements and the successful launch of new products, such as the HFX iQ™ system, which employs HFX AdaptivAI™ technology. This system aims to provide tailored pain relief for patients suffering from chronic conditions, which aligns with Globus's commitment to enhancing patient outcomes. The acquisition is seen as an opportunity for both companies to combine their resources, expertise, and product portfolios, ultimately leading to enhanced solutions for chronic pain management.
The ongoing challenges in the medical device market, such as the decline in permanent implant and trial procedures, underscore the necessity for consolidation and innovation in the industry. Nevro's focus on high-frequency spinal cord stimulation therapy, which has shown promising results for diabetic neuropathy patients, complements Globus Medical's existing offerings and enhances its capabilities in treating complex pain conditions. As the medical landscape continues to evolve, this acquisition positions Globus Medical as a more formidable player in the chronic pain treatment space, allowing it to address patient needs effectively and expand its market reach.
In other relevant news, Nevro's adjusted EBITDA for the year surpasses expectations, showcasing robust financial management despite recent revenue challenges. Recent publications highlighting the efficacy of Nevro’s SI Joint Fusion System over traditional treatments further bolster the company’s credibility in the medical community. This backdrop of innovation and strategic alignment lays the groundwork for a successful partnership between Globus Medical and Nevro, providing a pathway to advance chronic pain management solutions.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

